| Not Yet Recruiting | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML NCT07157514 | Actinium Pharmaceuticals | Phase 2 / Phase 3 |
| Recruiting | Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood NCT06904482 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis NCT06680661 | Leland Metheny | Phase 2 |
| Recruiting | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies NCT06656494 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Role of BMP Pathway in MDS Progression NCT06175923 | Hospices Civils de Lyon | — |
| Withdrawn | Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory L NCT05321940 | Juan C. Ramos, MD | Phase 1 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous NCT05974150 | Carevive Systems, Inc. | — |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | LILRB4 STAR-T Cell Therapy for Monocytic Leukemia NCT05739409 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Unknown | Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis NCT04709458 | Taiga Biotechnologies, Inc. | Phase 1 |
| Withdrawn | Diagnosis and Treatment of Periodontal Disease in Patients With AML NCT04530695 | Masonic Cancer Center, University of Minnesota | N/A |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide NCT04904588 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Terminated | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies NCT04762875 | Ensoma | Phase 2 |
| Terminated | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome NCT05263271 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Phase 1 Study of SH1573 Capsules in Subjects With Refractory or Relapsed Acute Myelogenous Leukemia NCT04806659 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 |
| Suspended | Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) o NCT04278768 | Curis, Inc. | Phase 1 / Phase 2 |
| Terminated | Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous NCT04172844 | Medical College of Wisconsin | Phase 1 |
| Active Not Recruiting | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With R NCT03971799 | Center for International Blood and Marrow Transplant Research | Phase 1 / Phase 2 |
| Terminated | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies NCT03214666 | GT Biopharma, Inc. | Phase 1 / Phase 2 |
| Completed | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy NCT04014764 | Notable Labs | — |
| Terminated | FT516 in Subjects With Advanced Hematologic Malignancies NCT04023071 | Fate Therapeutics | Phase 1 |
| Completed | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers NCT03761914 | Sellas Life Sciences Group | Phase 1 / Phase 2 |
| Completed | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cel NCT03755414 | Washington University School of Medicine | Phase 1 |
| Completed | Bisantrene for Relapsed /Refractory AML NCT03820908 | Sheba Medical Center | Phase 2 |
| Terminated | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia NCT03904251 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Withdrawn | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS NCT03059615 | Immune System Key Ltd | Phase 2 |
| Active Not Recruiting | Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients NCT03679650 | Beth Israel Deaconess Medical Center | Phase 1 |
| Completed | Resiliency in Older Adults Undergoing Bone Marrow Transplant NCT04188678 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | — |
| Completed | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS NCT03459859 | Justin Watts, MD | Phase 1 |
| Terminated | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy fo NCT03152526 | Miltenyi Biotec B.V. & Co. KG | N/A |
| Unknown | Medium Dose of Cytarabine and Mitoxantrone NCT04024241 | Shenzhen People's Hospital | — |
| Completed | Epigenetic Reprogramming in Relapse/Refractory AML NCT03263936 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Active Not Recruiting | DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission NCT03059485 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies NCT02991898 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF- NCT02773732 | University of Florida | Phase 1 / Phase 2 |
| Completed | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine NCT02996773 | University of Arizona | Phase 1 |
| Unknown | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML NCT02944162 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Completed | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Mali NCT02730312 | Xencor, Inc. | Phase 1 |
| Unknown | Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemothera NCT02802267 | Hybrigenics Corporation | Phase 2 |
| Active Not Recruiting | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leu NCT02665065 | Actinium Pharmaceuticals | Phase 3 |
| Completed | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 NCT02719574 | Forma Therapeutics, Inc. | Phase 1 / Phase 2 |
| Terminated | MCLA-117 in Acute Myelogenous Leukemia NCT03038230 | Merus B.V. | Phase 1 |
| Completed | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplan NCT02639559 | Washington University School of Medicine | Phase 2 |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007 | Northside Hospital, Inc. | Phase 2 |
| Unknown | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML a NCT02576301 | Mateon Therapeutics | Phase 1 / Phase 2 |
| Completed | MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients NCT02395822 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies NCT02543879 | Forma Therapeutics, Inc. | Phase 1 |
| Completed | Intra-Osseous Co-Transplant of UCB and hMSC NCT02181478 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Terminated | iCare for Cancer Patients NCT02435550 | University of Florida | N/A |
| Completed | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplan NCT02458235 | University of California, San Francisco | Phase 2 |
| Terminated | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS NCT02477787 | Asan Medical Center | Phase 2 |
| Terminated | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia NCT02323113 | Calithera Biosciences, Inc | Phase 1 / Phase 2 |
| Completed | Study of TCP-ATRA for Adult Patients With AML and MDS NCT02273102 | University of Miami | Phase 1 |
| Unknown | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood He NCT02338479 | Center for International Blood and Marrow Transplant Research | — |
| Withdrawn | Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation NCT01483274 | University of Louisville | Phase 1 |
| Completed | A Pilot RCT of the PRISM Intervention for AYAs With Cancer NCT02340884 | Seattle Children's Hospital | Phase 2 |
| Terminated | Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML NCT02255162 | Massachusetts General Hospital | Phase 1 |
| Completed | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acu NCT02287233 | AbbVie | Phase 1 / Phase 2 |
| Completed | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies NCT02566395 | Northwell Health | Phase 3 |
| Completed | A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML NCT02326584 | Seagen Inc. | Phase 1 |
| Terminated | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogeno NCT02319369 | Daiichi Sankyo | Phase 1 |
| Completed | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic NCT02296242 | BioMed Valley Discoveries, Inc | Phase 1 / Phase 2 |
| Terminated | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute NCT02203773 | AbbVie | Phase 1 |
| Terminated | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS NCT02267863 | Aptose Biosciences Inc. | Phase 1 |
| Completed | Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients NCT02109744 | University of Rochester | Phase 1 / Phase 2 |
| Completed | A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML NCT02040506 | Igenica Biotherapeutics, Inc. | Phase 1 |
| Completed | Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML) NCT01397799 | Kinex Pharmaceuticals Inc. | Phase 1 |
| Completed | Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. NCT02017457 | Carlos Graux, MD, PhD | Phase 2 |
| Terminated | AHN-12 Biodistribution in Advanced Leukemia NCT01207076 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplant NCT01634217 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) NCT01994837 | AbbVie | Phase 2 |
| Withdrawn | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in Fi NCT01639456 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Mal NCT01854567 | Mesoblast, Ltd. | Phase 3 |
| Completed | A Safety Study of SGN-CD33A in AML Patients NCT01902329 | Seagen Inc. | Phase 1 |
| Completed | Brentuximab Vedotin + Re-induction Chemotherapy for AML NCT01830777 | Massachusetts General Hospital | Phase 1 |
| Completed | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor NCT01696461 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Completed | Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Ar NCT01814826 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Alisertib for Acute Myeloid Leukemia NCT01779843 | Massachusetts General Hospital | Phase 1 |
| Completed | Human Placental-Derived Stem Cell Transplantation NCT01586455 | New York Medical College | Phase 1 |
| Completed | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia NCT01842672 | New York Medical College | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant NCT01744223 | Bellicum Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transpla NCT01795378 | Asan Medical Center | Phase 1 / Phase 2 |
| Terminated | Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syn NCT01795924 | Biosuccess Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia NCT01736943 | Joseph Tuscano | Phase 2 |
| Terminated | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylax NCT01749111 | Hospital Israelita Albert Einstein | Phase 3 |
| Terminated | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Mal NCT01745913 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Lenalidomide Plus Chemotherapy for AML NCT01681537 | Massachusetts General Hospital | Phase 1 |
| Completed | Double Cord Versus Haploidentical (BMT CTN 1101) NCT01597778 | Medical College of Wisconsin | Phase 3 |
| Completed | MRI Assessment of Leukemia Response to Therapy NCT01537159 | OHSU Knight Cancer Institute | — |
| Completed | A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) NCT01358734 | Celgene | Phase 2 |
| Terminated | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives NCT01532635 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Unknown | The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leuk NCT01556477 | Nordic MDS Group | Phase 2 |
| Completed | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell NCT01660607 | Stanford University | Phase 1 / Phase 2 |
| Completed | SCT Plus Immune Therapy in Average Risk AML/MDS NCT02117297 | New York Medical College | Phase 2 |
| Withdrawn | Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction NCT00967512 | Eleos, Inc. | Phase 2 |
| Completed | Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematolo NCT01491958 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS NCT02221310 | New York Medical College | Phase 2 |
| Completed | Reduced Intensity Double Umbilical Cord Blood Transplantation NCT01408563 | Massachusetts General Hospital | Phase 2 |
| Unknown | Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion NCT01513109 | Jules Bordet Institute | Phase 1 / Phase 2 |
| Terminated | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelo NCT01486784 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Terminated | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell NCT01500161 | Texas Oncology Cancer Center | Phase 2 |
| Terminated | T-Cell Depleted Double UCB for Refractory AML NCT01464359 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) NCT01385423 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Selecting a Favorable KIR Donor in Unrelated HCT for AML NCT01288222 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation NCT01338987 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myel NCT00892190 | University of Pittsburgh | Phase 1 |
| Terminated | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation NCT01326728 | National Cancer Institute (NCI) | — |
| Terminated | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation NCT01300611 | Tarix Pharmaceuticals | Phase 1 |
| Completed | Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AM NCT00943943 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patien NCT01200355 | Memorial Sloan Kettering Cancer Center | Phase 4 |
| Terminated | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equa NCT01193400 | PETHEMA Foundation | Phase 2 |
| Terminated | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL NCT01187810 | South Plains Oncology Consortium | Phase 1 |
| Completed | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody NCT01120457 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) NCT01160354 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed A NCT02662920 | Wake Forest University Health Sciences | — |
| Terminated | Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation NCT01366612 | Hackensack Meridian Health | Phase 3 |
| Completed | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias NCT01149915 | Threshold Pharmaceuticals | Phase 1 |
| Completed | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Is NCT01119066 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) NCT01145846 | Cooperative Study Group A for Hematology | Phase 3 |
| Completed | Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission NCT01096602 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies NCT01110473 | AbbVie (prior sponsor, Abbott) | Phase 1 |
| Completed | A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML) NCT01090167 | Genzyme, a Sanofi Company | Phase 1 |
| Unknown | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia NCT01037556 | Proacta, Incorporated | Phase 1 / Phase 2 |
| Unknown | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML NCT01146262 | Nantes University Hospital | Phase 1 / Phase 2 |
| Completed | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis NCT00954941 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975 | Indiana University School of Medicine | Phase 2 |
| Completed | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine NCT00995332 | University of Bergen | Phase 1 / Phase 2 |
| Completed | Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemia NCT00981240 | Sanofi | Phase 1 |
| Completed | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenou NCT00880269 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic S NCT00875693 | Weill Medical College of Cornell University | Phase 1 |
| Completed | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leu NCT00911066 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia NCT00923234 | Technische Universität Dresden | Phase 1 |
| Completed | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrom NCT00882102 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplasti NCT00830518 | Millennium Pharmaceuticals, Inc. | Phase 2 |
| Completed | Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adul NCT02662933 | Wake Forest University Health Sciences | N/A |
| Completed | Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome NCT00360672 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies NCT00719836 | S*BIO | Phase 1 / Phase 2 |
| Completed | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia NCT02007863 | University of Miami | N/A |
| Terminated | Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemi NCT00720850 | Technische Universität Dresden | Phase 2 |
| Completed | A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS NCT00656448 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR NCT01611298 | Robert Krance | N/A |
| Completed | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome NCT00968071 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transp NCT00674427 | University of Pennsylvania | Phase 1 |
| Completed | Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) NCT00686543 | Merck Sharp & Dohme LLC | Phase 4 |
| Terminated | In-Vivo Activated T-Cell Depletion to Prevent GVHD NCT00594308 | Indiana University | N/A |
| Completed | The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients NCT00726934 | Indiana University | N/A |
| Completed | A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) NCT00510133 | Asterias Biotherapeutics, Inc. | Phase 2 |
| Terminated | Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Stu NCT00486265 | AstraZeneca | Phase 1 |
| Terminated | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) NCT00579111 | Baylor College of Medicine | Phase 1 / Phase 2 |
| Completed | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD NCT00539695 | Baylor College of Medicine | Phase 2 |
| Completed | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL NCT00529360 | New York Medical College | Phase 1 / Phase 2 |
| Completed | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplant NCT00374933 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia NCT02113319 | University Hospital, Angers | Phase 2 |
| Completed | Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia NCT00623935 | University of Michigan Rogel Cancer Center | Phase 2 |
| Terminated | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML NCT00430443 | Callisto Pharmaceuticals | Phase 1 |
| Terminated | Effectiveness of Protected Environment Rooms for AML and MDS NCT00443300 | M.D. Anderson Cancer Center | — |
| Completed | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemi NCT00414310 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT NCT00412360 | Medical College of Wisconsin | Phase 3 |
| Completed | Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections NCT00418951 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (A NCT00495287 | Northern Italy Leukemia Group | Phase 3 |
| Completed | A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) NCT00373529 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants NCT00378534 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemi NCT00317642 | Genzyme, a Sanofi Company | Phase 3 |
| Completed | Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) NCT00398983 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Terminated | Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia NCT01289678 | Leo W. Jenkins Cancer Center | Phase 2 |
| Terminated | An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leuk NCT00346632 | Kyowa Kirin, Inc. | Phase 1 |
| Completed | AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia NCT00321581 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. NCT00315705 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HC NCT00285259 | Astellas Pharma Inc | Phase 2 |
| Completed | Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies NCT00270881 | Keio University | Phase 1 / Phase 2 |
| Completed | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or A NCT00324220 | Mirati Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia ( NCT00569010 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting NCT01031498 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Pa NCT00382590 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS NCT00334074 | Baylor Research Institute | Phase 2 |
| Completed | Phase II 5-Azacytidine Plus VPA Plus ATRA NCT00326170 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome NCT00760084 | Eisai Inc. | Phase 2 |
| Completed | Unrelated Donor Stem Cell Transplantation NCT01364363 | Scripps Health | N/A |
| Completed | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myel NCT00274248 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) NCT00106600 | CTI BioPharma | Phase 1 / Phase 2 |
| Completed | Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Tra NCT00303667 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Differentiation Induction in Acute Myelogenous Leukemia NCT00175812 | University of Bergen | Phase 1 / Phase 2 |
| Completed | Low Dose Melphalan and Bortezomib for AML and High-Risk MDS NCT00789256 | Dartmouth-Hitchcock Medical Center | N/A |
| Completed | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. NCT00299780 | Massachusetts General Hospital | Phase 1 |
| Completed | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP NCT00088231 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) NCT00459524 | M.D. Anderson Cancer Center | — |
| Completed | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML NCT00074737 | Eleos, Inc. | Phase 2 |
| Unknown | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family D NCT00304720 | Colorado Blood Cancer Institute | Phase 2 |
| Enrolling By Invitation | Biology Studies of Hematologic Cancers NCT00923442 | National Cancer Institute (NCI) | — |
| Completed | Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML NCT00382954 | University of Kentucky | Phase 1 |
| Terminated | Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CM NCT00074750 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation NCT00144677 | Dana-Farber Cancer Institute | Phase 2 |
| Terminated | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia NCT00104468 | SGX Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorde NCT00516152 | University of California, San Francisco | Phase 2 |
| Completed | Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia NCT01020539 | Columbia University | Phase 1 |
| Completed | Investigation of Clofarabine in Acute Leukemias NCT00098033 | University of Texas | Phase 2 |
| Terminated | Study of Gelonin Purging of Autologous Stem Cells for Transplantation NCT00043810 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia NCT00044889 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) NCT00064584 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) NCT00184054 | University of Southern California | Phase 2 |
| Completed | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies NCT00683046 | University of Chicago | Phase 2 |
| Completed | Nonmyeloablative Allogeneic Transplant NCT01272817 | Scripps Health | N/A |
| Completed | High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML NCT00474006 | Cooperative Study Group A for Hematology | Phase 3 |
| Recruiting | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Trans NCT01890486 | Wake Forest University Health Sciences | — |
| Completed | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS NCT00038831 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia NCT00116467 | Cell Genesys | Phase 2 |
| Withdrawn | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes NCT00038870 | M.D. Anderson Cancer Center | N/A |
| Completed | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant NCT00571662 | University of Nebraska | Phase 2 |
| Completed | A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia NCT00400673 | Northern Italy Leukemia Group | Phase 2 |
| Completed | Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant NCT00044733 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |
| Completed | Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasi NCT00136422 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow NCT00003838 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Mye NCT00136461 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) NCT00015587 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) NCT00136448 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS NCT00396968 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Withdrawn | A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered I NCT00297921 | Millennium Pharmaceuticals, Inc. | Phase 1 / Phase 2 |